Karimi-Zarchi Mojgan, Schwartz David A, Bahrami Reza, Dastgheib Seyed Alireza, Javaheri Atiyeh, Tabatabaiee Razieh Sadat, Ferdosian Farzad, Asadian Fatemeh, Neamatzadeh Hossein
Department of Obstetrics and Gynecology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran
Department of Pathology, Medical College of Georgia, Augusta, GA, USA
Turk J Obstet Gynecol. 2021 Sep 27;18(3):224-235. doi: 10.4274/tjod.galenos.2021.66750.
Preeclampsia and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection are both life-threatening disorders when they occur during pregnancy. They are similarly characterized by systemic immune activation and have a deleterious effect on maternal endothelial cells. During the coronavirus disease-2019 (COVID-19) pandemic, there were reports of preeclampsia or a preeclampsia-like syndrome occurring in pregnant women with SARS-CoV-2 infection. We performed a meta-analysis to estimate the risk and prevalence of preeclampsia and SARS-CoV-2 infection in pregnant women. A comprehensive literature search was conducted in PubMed, Web of Science, Scopus, and China National Knowledge Infrastructure to identify all relevant studies published up to February 29, 2020. All studies that reported the prevalence of preeclampsia in pregnant women with SARS-CoV-2 infection were selected. A total of 10 case-control studies and 15 case series met our inclusion criteria. Pooled data revealed no significant difference between infected pregnant women and uninfected pregnant women for the risk of preeclampsia [odds ratio (OR)=1.676, 95% confidence interval (CI) 0.679-4.139, p=0.236]. The stratified analysis revealed significant risk in the infected Asian pregnant women (OR=2.637, 95% CI 1.030-6.747, p=0.043), but not Caucasian. The prevalence of preeclampsia was 8.2% (95% CI 0.057-0.117) in infected pregnant women with COVID-19 in the overall population. Its prevalence was highest in North America (10.7%), followed by Asian (7.9%), Caucasian (6.7%), European (4.9%), and West Asian (2.6%) infected pregnant women. Our pooled data showed that the prevalence of preeclampsia in pregnant women with SARS-CoV-2 infection was 8.2%. However, there was no increased risk of occurrence of preeclampsia among pregnant women with SARS-CoV-2 infection.
子痫前期和严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染在孕期发生时均为危及生命的疾病。它们的相似之处在于均表现为全身免疫激活，且对母体内皮细胞有有害影响。在2019冠状病毒病（COVID-19）大流行期间，有报告称感染SARS-CoV-2的孕妇出现了子痫前期或子痫前期样综合征。我们进行了一项荟萃分析，以评估孕妇子痫前期和SARS-CoV-2感染的风险及患病率。在PubMed、科学网、Scopus和中国知网进行了全面的文献检索，以识别截至2020年2月29日发表的所有相关研究。选择了所有报告感染SARS-CoV-2的孕妇子痫前期患病率的研究。共有10项病例对照研究和15个病例系列符合我们的纳入标准。汇总数据显示，感染孕妇和未感染孕妇患子痫前期的风险无显著差异[比值比（OR）=1.676，95%置信区间（CI）0.679 - 4.139，p = 0.236]。分层分析显示，感染的亚洲孕妇存在显著风险（OR = 2.637，95%CI 1.030 - 6.747，p = 0.043），而白种孕妇则无。在总体人群中，感染COVID-19的孕妇子痫前期患病率为8.2%（95%CI 0.057 - 0.117）。其患病率在北美最高（10.7%），其次是亚洲（7.9%）、白种（6.7%）、欧洲（4.9%）和西亚（2.6%）感染孕妇。我们的汇总数据显示，感染SARS-CoV-2的孕妇子痫前期患病率为8.2%。然而，感染SARS-CoV-2的孕妇发生子痫前期的风险并未增加。
